Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized comparison of empagliflozin, pioglitazone, and semaglutide effects on adipose tissue in type 2 diabetes
2021-002367-21Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- Sep 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin, Pioglitazone and Semaglutide (3 arms). Started Sep 2021; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-002367-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002367-21.